Prognostic value of point-of-care testing for cardiac myosin-binding protein C in early risk assessment of acute myocardial infarction: a prospective cohort study

Figures

• 

  Fig. 1. Flow diagram.

• 

  Fig. 2. A ROC Curves of 5 Biomarkers for 30-Day MACE Prediction in AMI Patients. B Time-dependent predictive performance of biomarkers for 30-Day MACE in AMI patients.

• 

  Fig. 3. A Cross-Validated Error Curve for the LASSO Regression Model. B LASSO Coefficient Profiles of Analyzed Variables. Note (A) Relationship between the cross-validated error (y-axis) and log(λ) (x-axis). The red dashed vertical line indicates the optimal penalty parameter (log(λ) = –3.3) selected by tenfold cross-validation, corresponding to the minimum mean cross-validated error.(B) LASSO coefficient paths for the 39 analyzed clinical variables. Each line represents the trajectory of a variable’s coefficient as log(λ) increases. The red dashed vertical line marks the optimal log(λ) of –3.3, at which 14 variables retained non-zero coefficients and were selected for further analysis. Continuous biomarkers with skewed distributions, including cMyC and hs-cTnI, were log-transformed, and NT-proBNP was scaled by dividing by 100.

• 

  Fig. 4. A Kaplan–Meier Curves for 7-Day MACE by cMyC Group. B Kaplan–Meier Curves for 30-Day MACE by cMyC Group. C Kaplan–Meier Curves for 365-Day MACE by cMyC Group. D Kaplan–Meier Curves for 365-Day All-Cause Mortality by cMyC Group. Note The Kaplan–Meier survival curves show the cumulative incidence of major adverse cardiovascular events (MACE) and all-cause mortality over 7 days, 30 days, and 365 days, stratified by cMyC group. The log-rank test was used to compare survival distributions between groups, with a significant difference observed (P < 0.001).

• 

  Fig. 5. Forest Plot of Subgroup Analyses for cMyC Groups and 30-Day MACE. Note Hazard ratios (HRs) and 95% confidence intervals (CIs) for the association of cMyC groups (group 2 and group 3, with group 1 as reference) with 30-day major adverse cardiovascular events (MACE) across various patient subgroups. The cMyC group 2 and group 3 are represented by blue and red markers, respectively, with horizontal lines indicating 95% CIs. P values for interaction were calculated to test for effect modification by each subgroup. The vertical dashed line represents the null value (HR = 1). The numbers of patients and percentages in each subgroup are provided. All analyses were performed using Cox proportional hazards models.